TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7849967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FDA treatment)
Study: 29180457
Drug: β-blocker (Bbl)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker (Bbl)
Study: 16783479
Drug: AM-24 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-24 (500 mg once daily)
Study: 16783479
Drug: AM-24 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-24 (240 mg and 350 mg doses also administered)
Study: 8445423
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d
Study: 29861249
Drug: Zumba dancing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zumba dancing performed twice a week for 12 weeks
Study: 23902955
Drug: PDF (per
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDF (per 100 mL: 67 kcal, 1.7 g protein, 65 mg calcium, 38 mg phosphorus, 56 IU vitamin D)
Study: 23902955
Drug: TF (per
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF (per 100 mL: 67 kcal, 1.47 g protein, 50 mg calcium, 30 mg phosphorus, 48 IU vitamin D)
Study: 14708472
Drug: Basal (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal (no treatment)
Study: 3623787
Drug: Reinfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinfusion of autologous blood (1350 ml)
Study: 31691053
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (G2, n = 26), generator probe type 3, working time per point 5 s, 23 points, application time 1 min and 55 s
Study: 21118369
Drug: HA330 hemoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA330 hemoperfusion treatment (N=24)
Study: 21118369
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (N=20)
Study: 14600520
Drug: TMC125 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC125 (900 mg twice daily for 7 days)
Study: 10080589
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 2,510 mg/m2/d for 2 weeks followed by a 1-week rest period, repeated in 3-week cycles.
Study: 7813270
Drug: Aerosolized norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized norepinephrine (NE) 0.04 mg
Study: 1763589
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg bolus followed by 5 mg infusion over 1 h) + TENS (low or high frequency)
Study: 6410971
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) 1 mg intravenously as a bolus dose, followed by 1 mg infused over 5 minutes, then 1 mg intravenously every 12 hours for 3 days
Study: 28960164
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI) delivered by a supervised sleep educator
Study: 27329400
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg, 3 times a day for 16 weeks
Study: 23873891
Drug: Bimatoprost ophthalmic
Normalized name: bimatoprost ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost ophthalmic solution 0.03%
Study: 21914755
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (2 mL 0.9% saline)
Study: 21914755
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline group (30 mL 0.9% saline)
Study: 21914755
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid group (40 mg triamcinolone acetonide in 29 mL 0.9% saline)
Study: 19052125
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a at a dosage of 90 microg per week for 3.5 years
Study: 16801668
Drug: Folate 1
Normalized name: Elfolate 15mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate 1 mg/vitamin B(12) 500 microg
Study: 11061655
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose therapy with zidovudine, lamivudine, and indinavir
Study: 9357394
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg seratrodast
Study: 9357394
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg seratrodast
Study: 8260471
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g protein/kg per d
Study: 8260471
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g protein/kg per d
Study: 8260471
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g protein/kg per d
Study: 8260471
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g protein/kg per d
Study: 26860802
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment (herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21), Chinese acupoint application (d1-d21))
Study: 26860802
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed (500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8))
Study: 20829132
Drug: Ezetimibe (EZM)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZM) preparation 1
Study: 20829132
Drug: Ezetimibe (EZM)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZM) preparation 2
Study: 16866719
Drug: Topiramate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (mean dose 124.7 mg/d)
Study: 12811613
Drug: Infrared lasertherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared lasertherapy - Group L; n=20
Study: 10743866
Drug: 25% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% metronidazole gel applied during periodontal surgery
Study: 10743866
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + 25% metronidazole gel
Study: 9184738
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg tablets/2 mg dose)
Study: 9184738
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg tablets/8 mg dose)
Study: 9184738
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg tablets/10 mg dose)
Study: 1524898
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (BCT) - lumpectomy, axillary clearance, and radiotherapy (50 Gy in 5 weeks external irradiation and a boost with iridium implant of 25 Gy)
Study: 1524898
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment for local recurrence
Study: 31356921
Drug: ASN002 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN002 (20 mg)
Study: 31356921
Drug: ASN002 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN002 (40 mg)
Study: 31356921
Drug: ASN002 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN002 (80 mg)
Study: 26259770
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of 100×10(6) autologous bone marrow mononuclear cells
Study: 23329566
Drug: Health facilities
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health facilities with adequate staffing and availability of medical equipment and medications
Study: 21521310
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg and cholecalciferol 5600 IU (RSD+)
Study: 21521310
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg alone (RSD)
Study: 18645245
Drug: Soft-gel capsules
Normalized name: Fortovase 200 MG Soft-Gel Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-gel capsules with CoQ10 in soybean oil (reference)
Study: 16155071
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (600 microg every 3 h for a maximum of three doses)
Study: 16155071
Drug: Extended course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended course of sublingual misoprostol (400 microg daily for 1 week)
Study: 16155071
Drug: Extended course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended course of sublingual misoprostol
Study: 11219162
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation and measles vaccine interaction
Study: 8808520
Drug: KCl (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCl (7 mEq in 200 mL of 0.9% NaCl)
Study: 8808520
Drug: MgSO4 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (10 mL 20% in 200 mL of 0.9% NaCl)
Study: 8808520
Drug: Procainamide (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (maximal dose, 10 mg/kg of body weight over a 5‐minute period)
Study: 8808520
Drug: NaCl (0.9%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (0.9%, 200 mL)
Study: 1329220
Drug: Combination carboplatin/etoposide/vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination carboplatin/etoposide/vincristine (CEV)
Study: 4057572
Drug: PAV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAV therapy in stage IV cases
Study: 4057572
Drug: PAV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAV therapy in operable cases
Study: 4057572
Drug: Bestatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin treatment in stage Ib and II cases
Study: 4057572
Drug: PPSM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSM treatment with prophylactic lymph node dissection
Study: 4057572
Drug: PPSM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPSM treatment without prophylactic lymph node dissection
Study: 30366505
Drug: Adaptive Iterative
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Iterative Dose Reduction 3D (AIDR3D) with 80 kV and auto mA (Group B)
Study: 24731889
Drug: Osteopathic sham
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic sham therapy
Study: 20853611
Drug: V1 -
Normalized name: SODIUM MOLYBDATE (V1) 50MIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: V1 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 of a 21-day cycle
Study: 20853611
Drug: V2 -
Normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: V2 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 20 mg orally on day 2 of a 28-day cycle
Study: 1959461
Drug: Prazosin (alpha-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (alpha-adrenergic blocker)
Study: 28035659
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing for food additives
Study: 19920724
Drug: Low-frequency pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency pulsed electromagnetic field (PEMF) therapy
Study: 26440233
Drug: Ketamine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.8 mg/kg
Study: 9034275
Drug: Prophylactic ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic ranitidine treatment for 4 days
Study: 9034275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ranitidine treatment)
Study: 9034275
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment for infant respiratory distress syndrome
Study: 22230963
Drug: LigaSure LF1212
Approvals — FDA: no, EMA: no, PMDA: no
Description: LigaSure LF1212 (L)
Study: 20378080
Drug: Mipomersen 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 100 mg/week and higher
Study: 20378080
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg/week (13-week cohort)
Study: 15791113
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g)
Study: 8748429
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of nefazodone (NEF) twice daily
Study: 8748429
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of lorazepam (LOR) twice daily
Study: 8748429
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 mg of LOR and 200 mg of NEF (LOR+NEF) twice daily
Study: 8748429
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) twice daily
Study: 31238161
Drug: Abatacept therapy
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept therapy (weekly or every other week administration)
Study: 31238161
Drug: Abatacept therapy
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept therapy
Study: 31238161
Drug: Abatacept therapy
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept therapy (every 4 weeks)
Study: 27307704
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 3-monthly injections (PP-3M)
Study: 17560664
Drug: Acetaminophen +
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen + diphenhydramine + pseudoephedrine (Group-1)
Study: 17560664
Drug: Acetaminophen only
Normalized name: Acetaminophen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen only (Group-2)
Study: 11597378
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine (OP)
Study: 9855155
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% verapamil (single drop)
Study: 9855155
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% verapamil (2-week administration)
Study: 9855155
Drug: Placebo (2-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2-week administration)
Study: 2925973
Drug: Insight-oriented marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight-oriented marital therapy (IOMT)
Study: 2925973
Drug: Treatment-on-demand (TOD)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-on-demand (TOD) waiting-list control group
Study: 18321745
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.01% raspberry ketone (RK)
Study: 14522625
Drug: 2% licorice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% licorice topical gel
Study: 14522625
Drug: 1% licorice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% licorice topical gel
Study: 14522625
Drug: Base gel
Normalized name: Orabase Gel-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base gel (control)
Study: 1599063
Drug: Transdermal hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal hyoscine (Scopoderm TTS CIBA)
Study: 27799756
Drug: Ectoin® inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ectoin® inhalation solution
Study: 20035240
Drug: Histone deacetylase
Normalized name: Histone deacetylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histone deacetylase inhibitor vorinostat
Study: 15823183
Drug: Fluticasone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone administered twice daily
Study: 15823183
Drug: Fluticasone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone administered once daily
Study: 11956267
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with Melacine vaccine
Study: 11956267
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with Melacine vaccine among HLA-A2-positive and/or HLA-C3-positive patients
Study: 322821
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g amoxycillin plus 1 g probenecid
Study: 322821
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g amoxycillin plus 1 g probenecid
Study: 26999837
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid + intratympanic steroid as supplementary treatment (group A)
Study: 26999837
Drug: Initial intratympanic
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial intratympanic steroid (group B)
Study: 26999837
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid as supplementary treatment (12 patients in group A)
Study: 15151263
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy (0.25 IU/kg subcutaneously 3x/week after each dialysis session)
Study: 9294877
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (18.75 g creatine monohydrate daily for 5 days prior to and 2.25 g creatine daily during testing)
Study: 9294877
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g of calcium chloride daily for 5 days prior to the first set of work bouts)
Study: 29550238
Drug: High-flow therapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow therapy with 'rescue' CPAP backup
Study: 29550238
Drug: High-flow therapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow therapy without 'rescue' CPAP backup
Study: 23662515
Drug: Unbalanced solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbalanced solutions in infusion therapy
Study: 23662515
Drug: Balanced solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solutions in infusion therapy
Study: 20230331
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5mg tablets daily for 4 weeks
Study: 12138953
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) for 14 weeks
Study: 2143104
Drug: Trospectomycin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin (75 to 1,000 mg)
Study: 2143104
Drug: Trospectomycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin (600 mg and above)
Study: 2143104
Drug: Trospectomycin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin (1,000 mg)
Study: 841605
Drug: Irradiation under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irradiation under 95% O2 plus 5% CO2 inhalation
Study: 30958319
Drug: Cathodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal transcranial direct current stimulation over the contralesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation in combination with robotic training
Study: 30958319
Drug: Cathodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal transcranial direct current stimulation over the ipsilesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation in combination with robotic training
Study: 25877495
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin supplementation (folic acid 0.8 mg, vitamin B-6 20 mg, vitamin B-12 0.5 mg)
Study: 24032554
Drug: ixekizumab 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixekizumab 10, 25, 75 or 150 mg subcutaneously
Study: 19538811
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1000 mg Ca)
Study: 19538811
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (1000 mg Ca)
Study: 19538811
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (2250 mg K)
Study: 17091418
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine treatment
Study: 11894976
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (0.45 g ethanol/kg)
Study: 9592984
Drug: Aprotinin (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high-dose, continuous intravenous infusion)
Study: 3203010
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance therapy consisting of thioguanine 100 mg/m2 twice daily and etoposide 100 mg/m2 twice daily (days 1-5) alternating with CCNU 50 mg/m2 once to a total of 6 courses.
Study: 28463149
Drug: Long-term ADT
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term ADT (LTAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month plus an additional 24 months of monthly goserelin)